S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
NASDAQ:GDRX

GoodRx (GDRX) Stock Price, News & Analysis

$7.10
+0.09 (+1.28%)
(As of 09:40 AM ET)
Today's Range
$7.03
$7.18
50-Day Range
$6.00
$8.35
52-Week Range
$4.14
$9.37
Volume
43,006 shs
Average Volume
1.68 million shs
Market Capitalization
$2.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.76

GoodRx MarketRank™ Stock Analysis

Analyst Rating
Hold
2.44 Rating Score
Upside/​Downside
25.0% Upside
$8.76 Price Target
Short Interest
Bearish
12.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of GoodRx in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
34.78%
From $0.23 to $0.31 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.88 out of 5 stars

Medical Sector

238th out of 939 stocks

Data Processing & Preparation Industry

15th out of 59 stocks

GDRX stock logo

About GoodRx Stock (NASDAQ:GDRX)

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. The company serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was founded in 2011 and is headquartered in Santa Monica, California.

GDRX Stock Price History

GDRX Stock News Headlines

This healthcare stock making a buzz with 160% growth (GDRX)
Healthcare stocks are typically on the boring side of the spectrum, that is until you add a bit of technology and the right niche to them.
GoodRx (NASDAQ:GDRX) Shares Gap Up to $6.58
CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
Why GoodRx Surged Today
CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
RSI Apr 2024 10.000 put
GoodRx Interim CEO Extends Commitment to Company
Trade GoodRx? What's the Rush?
Why GoodRx Stock Soared Today
See More Headlines
Receive GDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Data processing & preparation
Sub-Industry
N/A
Current Symbol
NASDAQ:GDRX
Fax
N/A
Employees
952
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.76
High Stock Price Target
$14.00
Low Stock Price Target
$4.50
Potential Upside/Downside
+25.0%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
18 Analysts

Profitability

Net Income
$-8,870,000.00
Pretax Margin
-7.41%

Debt

Sales & Book Value

Annual Sales
$750.27 million
Cash Flow
$0.41 per share
Book Value
$1.93 per share

Miscellaneous

Free Float
389,586,000
Market Cap
$2.77 billion
Optionable
Optionable
Beta
1.44
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

GDRX Stock Analysis - Frequently Asked Questions

Should I buy or sell GoodRx stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last year. There are currently 1 sell rating, 8 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GDRX, but not buy additional shares or sell existing shares.
View GDRX analyst ratings
or view top-rated stocks.

What is GoodRx's stock price target for 2024?

18 Wall Street research analysts have issued 1-year target prices for GoodRx's shares. Their GDRX share price targets range from $4.50 to $14.00. On average, they predict the company's share price to reach $8.76 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price.
View analysts price targets for GDRX
or view top-rated stocks among Wall Street analysts.

How have GDRX shares performed in 2024?

GoodRx's stock was trading at $6.70 at the beginning of 2024. Since then, GDRX stock has increased by 4.6% and is now trading at $7.01.
View the best growth stocks for 2024 here
.

When is GoodRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our GDRX earnings forecast
.

How were GoodRx's earnings last quarter?

GoodRx Holdings, Inc. (NASDAQ:GDRX) released its earnings results on Thursday, February, 29th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.02. The company had revenue of $196.64 million for the quarter, compared to the consensus estimate of $195.59 million. GoodRx had a positive trailing twelve-month return on equity of 2.45% and a negative net margin of 1.18%.

What ETFs hold GoodRx's stock?
What guidance has GoodRx issued on next quarter's earnings?

GoodRx issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $800.0 million-$800.0 million, compared to the consensus revenue estimate of $790.5 million.

What other stocks do shareholders of GoodRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX).

When did GoodRx IPO?

GoodRx (GDRX) raised $900 million in an initial public offering (IPO) on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays served as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

Who are GoodRx's major shareholders?

GoodRx's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.06%), Vanguard Group Inc. (2.12%), Rubric Capital Management LP (1.45%), Dimensional Fund Advisors LP (0.44%), Rip Road Capital Partners LP (0.43%) and Assenagon Asset Management S.A. (0.33%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Lake Group LLC Silver, Scott Wagner and Trevor Bezdek.
View institutional ownership trends
.

How do I buy shares of GoodRx?

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GDRX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners